Trial · NCT00740779

Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

NCT00740779, Phase 2, Completed, Watson Pharmaceuticals; results first posted 2012-02-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Trials, record NCT00740779. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00740779

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
NCT number: NCT00740779
Status: Completed
Phases: Phase 2
Enrollment: 153 participants, actual
Lead sponsor: Watson Pharmaceuticals
Conditions: Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Interventions: Silodosin 8 mg, Placebo, Silodosin 4 mg
First posted: 2008-08-25
Last updated: 2012-02-24
Results first posted: 2012-02-24

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.	12 weeks	Change from baseline In NIH-CPSI at Week 12. Three separate domain scores are calculated as pain, urinary symptoms, and quality of life impact. NIH-CPSI total score uses a 0 to 43 scale; 0 best, 43 worse symptoms.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.	12 weeks	The number of participants for analysis is determined by Last Observation Carried Forward (LOCF).	Units on a 0 to 43 scale	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.	Silodosin 4 mg	Baseline NIH-CPSI Total Score	26.0	Standard Deviation 6.29	Units on a 0 to 43 scale
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.	Silodosin 8 mg	Baseline NIH-CPSI Total Score	26.8	Standard Deviation 5.94	Units on a 0 to 43 scale
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.	Placebo	Baseline NIH-CPSI Total Score	27.9	Standard Deviation 6.21	Units on a 0 to 43 scale
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.	Silodosin 4 mg	Chage from Baseline in NIH-CPSI at Week 12	-12.1	Standard Deviation 9.32	Units on a 0 to 43 scale
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.	Silodosin 8 mg	Chage from Baseline in NIH-CPSI at Week 12	-10.2	Standard Deviation 8.84	Units on a 0 to 43 scale
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score.	Placebo	Chage from Baseline in NIH-CPSI at Week 12	-8.5	Standard Deviation 7.23	Units on a 0 to 43 scale

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Silodosin 4 mg	52
Overall Study	STARTED	Silodosin 8 mg	45
Overall Study	STARTED	Placebo	54
Overall Study	COMPLETED	Silodosin 4 mg	43
Overall Study	COMPLETED	Silodosin 8 mg	31
Overall Study	COMPLETED	Placebo	41
Overall Study	NOT COMPLETED	Silodosin 4 mg	9
Overall Study	NOT COMPLETED	Silodosin 8 mg	14
Overall Study	NOT COMPLETED	Placebo	13

Source ClinicalTrials.gov

Adverse events42

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Retrograde Ejaculation	Reproductive system and breast disorders	Silodosin 4 mg	14	52	15
other	Retrograde Ejaculation	Reproductive system and breast disorders	Silodosin 8 mg	18	45	18
other	Retrograde Ejaculation	Reproductive system and breast disorders	Placebo	1	54	1
other	Dizziness	Nervous system disorders	Silodosin 4 mg	1	52	1
other	Dizziness	Nervous system disorders	Silodosin 8 mg	5	45	5
other	Dizziness	Nervous system disorders	Placebo	4	54	5
other	Headache	Nervous system disorders	Silodosin 4 mg	1	52	1
other	Headache	Nervous system disorders	Silodosin 8 mg	2	45	3
other	Headache	Nervous system disorders	Placebo	2	54	2
other	Nasal Congestion	Respiratory, thoracic and mediastinal disorders	Silodosin 4 mg	2	52	2

1 to 10 of 42Source ClinicalTrials.gov

See all 42 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Silodosin 4 mg
Total, all-cause mortality	Silodosin 8 mg
Total, all-cause mortality	Placebo
Total, other adverse events	Silodosin 4 mg	22	52
Total, other adverse events	Silodosin 8 mg	25	45
Total, other adverse events	Placebo	12	54
Total, serious adverse events	Silodosin 4 mg	2	52
Total, serious adverse events	Silodosin 8 mg	0	45
Total, serious adverse events	Placebo	0	54

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
21571345	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00740779

GET https://conductscience.org/api/trials/v1/NCT00740779/events?page=2

API reference For AI assistants